Search 5-Amino-1MQ and half the results will call it a peptide. It is not one. It sits in the same vendor menus as BPC-157 and tesamorelin, gets discussed in the same threads, and inherited the label by association. That small error is a decent tell for how much of the online conversation is copied rather than understood, so this piece starts by getting the basics right and then follows the evidence as far as it fairly goes.
The straight answer up front is simple. 5-Amino-1MQ is a small synthetic molecule that blocks an enzyme called NNMT, and the interest in it is almost entirely about fat loss and metabolism. The mechanism is one of the more elegant stories in the space. The human data behind it is close to nonexistent. Both of those things are true at once, and most articles pick one and run with it.
What follows is the version that separates the animal work from the marketing, walks through how the enzyme behaves, grades every claim by how well it holds up, and covers dosing, the mistake that ruins most people’s results, legality in 2026, and how to buy it without paying for degraded powder in a clear vial.
5-Amino-1MQ Is Not a Peptide, and Why That Matters
Peptides are short chains of amino acids. 5-Amino-1MQ has no amino-acid chain at all. Its full name is 5-amino-1-methylquinolinium, it is built on a quinolinium ring, and the active part weighs in around 159 g/mol. Most peptides start north of 500 g/mol. It was developed by the Watowich lab at the University of Texas Medical Branch, which is where much of the foundational NNMT-inhibitor chemistry comes from.
Why does the distinction matter beyond pedantry? Because a small molecule and a peptide behave differently in the body. Small molecules like this one are often orally active, which is a big part of the appeal here and rare in a market full of injectables. A peptide framing also drags in assumptions about reconstitution, injection, and dosing that do not map cleanly onto what this compound is. Get the category right and the rest of the picture gets clearer.
One more boundary before we go deeper. This is not a substitute for semaglutide or tirzepatide, and it is not an approved weight-loss drug. Those are prescription medications with large trials behind them. 5-Amino-1MQ is an early research compound chasing a completely different target, which is exactly why it is interesting and exactly why the claims need grading.
If you are looking to get some now, the source we point people to is Everest Peptides. It is our own store, it ships a tested 50mg vial in light-blocking amber glass, and code BRAINFLOW takes 10% off. There is more on sourcing, dosing, and the evidence below.
Research Grade · Amber Glass Vial
Everest Peptides 5-Amino-1MQ, 50mg
Third-party tested by Freedom Diagnostics · shipped in a light-blocking amber vial
50mg per vial where plenty of vendors give you 10mg for similar money. On sale from $109.99 to $84.99, and code BRAINFLOW knocks off another 10%, to about $76.49.
Shop Everest 5-Amino-1MQ → 10% OffSold for research use only.
NNMT: The Enzyme 5-Amino-1MQ Is Built to Block
NNMT stands for nicotinamide N-methyltransferase. Its job is small and specific. It takes nicotinamide, a form of vitamin B3, and tags it with a methyl group borrowed from SAM, the cell’s main methyl donor. The output is 1-methylnicotinamide, and the nicotinamide that got tagged is now spent.
That is a bigger deal than it sounds. Nicotinamide is one of the raw materials cells recycle into NAD+, the coenzyme behind energy production and the sirtuins. When NNMT runs hot, it drains nicotinamide and eats through the methyl budget at the same time, which in certain tissues means less fuel for NAD+ and tighter methylation. NNMT happens to be busiest in fat and liver, and it shows up elevated in the fat of people and animals with obesity and insulin resistance.
The paper that launched all the attention is a 2014 study in Nature, where knocking NNMT down in fat and liver protected obese mice from diet-induced weight gain by raising energy expenditure. Think of NNMT as one dial on the panel that governs how fat cells handle energy and methyl traffic, not a single master switch.
The complication the marketing skips: NNMT is not uniformly the villain. In the liver, its activity can be protective and improve lipid handling, which is why reviewers have called it a bad actor in fat that makes good in liver. Blanket inhibition everywhere, forever, is not an obvious win. Biology rarely is.
What Blocking NNMT Does Inside a Fat Cell
When 5-Amino-1MQ inhibits NNMT, a handful of things shift in the lab models. Nicotinamide is spared and routed toward the NAD+ salvage pathway. Methyl groups are preserved instead of spent. Fat cells show smaller size and less lipid storage. Energy expenditure and oxygen consumption tick up, and sirtuin-related signaling gets nudged. In the headline animal work, obese mice on a selective NNMT inhibitor lost fat mass without eating less, which is the detail that makes people lean in, because it points at a metabolic effect rather than appetite suppression.
Two levers do most of the work in that story. The first is NAD+. Sparing nicotinamide feeds the salvage pathway that keeps NAD+ topped up, and NAD+ is what powers SIRT1, a sirtuin tied to mitochondrial biogenesis and metabolic efficiency. Restore the fuel and SIRT1 has more to work with, which is the thread that connects this compound to the wider NAD+ and longevity conversation. The second lever is the methyl budget. NNMT burns through SAM, the cell’s main methyl donor, so blocking it leaves more methyl groups in circulation for the reactions that regulate gene expression. In fat cells the combination reads as a shift from storing energy to spending it, which is why the animal data showed smaller adipocytes and higher oxygen consumption rather than a change in appetite.
The gap sits right underneath that tidy story. Oral bioavailability and half-life in humans have never been measured, and the standout mouse studies used injection. So how much of an oral dose reaches human fat tissue, and how long it stays active, is unknown. The pathway is real. The human translation is the open question, and no amount of confident vendor copy closes it.
5-Amino-1MQ Benefits, Graded by the Evidence
The benefits attached to 5-Amino-1MQ are not equal. Some have consistent preclinical support, some are reasonable inference, and some are gym-forum lore in a lab coat. The same evidence most articles bury in a wall of identical subheadings, sorted instead by how much weight each claim can bear.
Holds up (in animals)
Fat and body composition. A 2018 study in Biochemical Pharmacology showed selective NNMT inhibitors reversed diet-induced obesity in mice, shrinking fat mass and adipocyte size while leaving food intake and lean mass alone. A 2024 follow-up (Babula et al.) pushed the dose to roughly 32 mg/kg per day and reported around 72% suppression of fat-mass gain, with better glucose tolerance and less fatty liver. Energy expenditure rose in the original knockdown work too. Strong, specific, and entirely rodent.
Promising, but thin
Glucose and insulin sensitivity. NNMT inhibition improved glucose tolerance in animal models, and a 2021 review of NNMT in obesity and type 2 diabetes flatly noted no clinical trials have been reported. Muscle and recomposition get a nod from a 2019 study where an NNMT inhibitor improved muscle regeneration and strength in aged mice. The rationale is that NNMT climbs in aging skeletal muscle, dragging down the NAD+ salvage pathway and SIRT1 activity and pushing muscle stem cells toward senescence, so inhibiting it may help aged muscle repair and contract better. That is a real and interesting angle for sarcopenia, but “regeneration after injury in old mice” is still a long way from “builds muscle in a healthy lifter.”
Theory only
NAD+ boosting, mitochondrial function, longevity. Sparing nicotinamide plausibly supports the NAD+ salvage pathway, and a 2024 review framed NNMT as an aging target. But “may preserve NAD+ raw materials in some tissues” is not “an NAD+ booster like NMN,” and there is no human healthspan data. Treat these as mechanism that rhymes with longevity science, not evidence.
The line that ties it together is blunt. There are no published human clinical trials of 5-Amino-1MQ for weight loss, and as of 2026 there is no completed trial or published human safety data. Metabolism targets that dazzle in rodents have a long history of fizzling in people, because mouse fat is not human fat and short studies hide long-term problems. The preclinical signal here is unusually consistent, which is more than a lot of hyped compounds can say. It still is not proof.
5-Amino-1MQ Dosage and the mg vs mcg Trap
The real-world conversation is miles ahead of the research, so the ranges below come from clinic-style protocols, vendor pages, and user reports, not from validated trials. Read them as what people discuss, not as a recommendation.
Before the numbers, the mistake that sinks more attempts than anything else is a units error, milligrams versus micrograms. Someone reads a microgram figure, doses a thousandth of the intended amount, feels nothing, and writes the compound off. If a dose you see quoted looks 1,000 times smaller than everyone else’s, that is the bug, not a light protocol.
One reason some protocols split the daily amount is pharmacokinetics. Reported preclinical half-life lands somewhere around 3.8 to 6.9 hours, short enough that a single morning dose may not hold steady NNMT inhibition across the whole day. That is the logic behind twice-daily dosing, often something like 25 to 50 mg in the morning and the same in the early afternoon, to keep levels more even. None of that is confirmed in humans, so read it as reasoned convention rather than a validated schedule, and it is the same short half-life that makes late-day dosing a common culprit behind disrupted sleep.
The ramp most people describe is unremarkable and sensible. Start at 50 mg, hold there for two to four weeks to gauge tolerance, and only move toward 100 to 150 mg if the lower dose sits well. Nothing suggests starting high does anything except raise the odds of stomach upset. Cycle length is where conventions split. Some run the standard 8 to 12 weeks on with an equal break, others prefer shorter 20 to 30 day blocks followed by a one to two week pause, on the theory that a rest lets NAD+ metabolism resettle. There is no trial telling you which is right, so both are educated guesses.
Two principles hold across the reports. Mouse mg/kg dosing does not translate to a safe human oral dose, and more is not better. Stomach discomfort clusters at the top of the range, and there is no signal that pushing higher buys extra fat loss.
Oral capsules or injection?
Both formats show up in the wild. Injectable protocols are usually subcutaneous at roughly 50 mg a day or lower, and they carry the extra friction of reconstituting the powder with bacteriostatic water and keeping it cold. The interesting wrinkle is that oral is not obviously the weaker option, even though vendors often quote lower oral bioavailability. Part of the research suggests injected drug is cleared largely unchanged in the urine, which is one reason practitioners who like this compound tend to favour the oral route, and why 5-Amino-1MQ earned its reputation as one of the few orally active compounds in a market dominated by injectables. For most people the capsule or oral powder is simpler, cheaper, and the format the community leans on.
5-Amino-1MQ Results: What 8 to 12 Weeks Looks Like
Nobody has published a human before-and-after, so any “results timeline” is stitched from mouse data, vendor copy, and forum posts. With that stated plainly, the anecdotal pattern is fairly consistent. Early on, people mention steadier energy and focus, which fits the NAD+ story and could be partly placebo. Later, around the 8 to 12 week mark, body-composition changes get reported, and almost always alongside a real diet and training block. Remove the deficit and the training, and there is not much story left.
If you run it, measure instead of guessing. Baseline bloodwork before you start (fasting glucose, fasting insulin, HOMA-IR, HbA1c, a lipid panel, and ALT), then a recheck at 8 to 12 weeks, turns a vibe into data. It tells you whether anything metabolic is moving and flags liver or glucose issues early. That is the line between running an experiment and just hoping.
Stacks, and How It Compares to GLP-1 Drugs
The comparison people reach for first is “is this a natural Ozempic?” The honest answer is no, because they are not playing the same game. GLP-1 drugs like semaglutide and tirzepatide work on appetite, satiety, and blood sugar, and they carry a mountain of human trial data. Semaglutide averaged about 15% body-weight loss over 68 weeks in its big trial, tirzepatide pushed past 20% at the top dose, and newer triple agonists like retatrutide are posting bigger numbers still. 5-Amino-1MQ targets the metabolic side through NNMT and has no comparable human weight-loss data. One is an approved therapy, the other an early research compound. Not interchangeable.
That is also why 5-Amino-1MQ shows up as a stack partner rather than a standalone. The most common pairing is with a GLP-1, on the logic that the drug handles appetite while the compound works metabolism, with a hoped-for muscle-sparing bonus. It is a reasonable theory with zero combination trials behind it, and layering an experimental compound onto a prescription drug is exactly what needs a clinician in the loop. Beyond that, people mention tesamorelin for visceral fat, MOTS-c for the shared mitochondrial and AMPK angle, and older fat-loss peptides like AOD-9604, plus supplement-tier additions like NMN, berberine, metformin, L-carnitine, and creatine.
The unglamorous truth underneath every stack is that the calorie deficit, the protein, the training, and the sleep do the heavy lifting. In the mouse data, NNMT inhibition plus a reduced-calorie diet beat the diet alone, which frames this compound as an adjunct to the work, not a replacement for it. And the more experimental agents you pile on, the more you are running an uncontrolled trial on yourself.
5-Amino-1MQ Side Effects and the Open Questions
Vendor pages love “no known side effects.” Read that as “barely studied in people,” because there is no human safety data. In the mouse studies, researchers saw no obvious adverse effects at the doses tested and no cell toxicity in lab assays, but those are short animal studies.
From users, the picture skews mild. The most common complaint is sleep disruption with late dosing, which is why morning dosing is the standard workaround. Some report mild stomach upset at higher oral doses, usually eased by taking it with food. Appetite reports are all over the map. None of it is well characterized.
The theoretical concerns deserve respect precisely because the data is missing. NNMT sits at a methylation and NAD+ crossroads, so chronic manipulation could do things nobody is measuring, and its protective liver role means blanket long-term inhibition is not obviously harmless. Add unknown drug interactions and gray-market quality problems and the honest safety summary is a list of question marks. Pregnancy or breastfeeding, liver or kidney issues, a cancer history, or medications that touch methylation and metabolism all move this from “cautious” to “talk to a physician first.”
Is 5-Amino-1MQ Legal in 2026?
“You can buy it online” and “it is approved” are not the same sentence. The FDA has not approved 5-Amino-1MQ for weight loss or anything else, and it is not a recognized dietary supplement ingredient, so it cannot be lawfully sold as a supplement. That is why vendors slap “research use only, not for human consumption” on it, a label the FDA has repeatedly treated as meaningless when a product is clearly marketed and dosed for people.
The compounding angle is weaker than clinic marketing suggests. 5-Amino-1MQ is not on the FDA’s 503A bulk drug substances list, which is generally what a substance needs to be on for a pharmacy to compound it legitimately, and updated FDA guidance from early 2025 tightened the rules around compounding substances without established monographs. So “compounded” is not the reassurance it sounds like. For athletes there is a separate problem. Anything not approved for human therapeutic use falls under WADA’s catch-all for non-approved substances, so it is effectively banned in tested sport at all times.
Where to Buy 5-Amino-1MQ Without Getting Burned
This is the part that separates a real result from a waste of money, because the compound is sold as a research chemical in a market full of underdosed and mislabeled product. Three things decide whether you get what you pay for: a real certificate of analysis, a vendor that publishes third-party testing, and packaging that protects the material.
That last point gets ignored constantly. Like many research compounds, 5-Amino-1MQ can degrade with exposure to UV and ambient light, quietly shaving off the potency printed on the label. Clear glass does almost nothing about that. Amber glass blocks most of the UV and short-wavelength light that drives photodegradation, which is why serious labs store light-sensitive material in amber vials, cold and dark. Very few vendors bother. Everest is one of the ones that does, shipping it in an amber vial as standard on top of the Freedom Diagnostics testing.
Storage once it arrives is the other half of the equation. Sealed lyophilized powder is stable kept cool, dark, and dry, and long-term storage in a freezer around minus 20 Celsius is the standard for research material. If a batch is reconstituted for an injectable protocol, it moves to the fridge and has a much shorter usable window, which is one more reason the oral formats are simpler to live with. The short version is that a good vial handled badly still ends up weak, so cold, dark, and sealed is the rule from the moment it lands on your doorstep.
On value, the market norm is roughly 10mg for around $50. Everest runs 50mg per vial, on sale from $109.99 to $84.99, with another 10% off via code BRAINFLOW, landing near $76.49. It is our own store, so we know how it is handled, and for most people who want tested, well-packaged material it is the pick. If the priority is the lowest upfront cost, Amino Club is a solid lab-tested powder alternative with 30% off using code BRAINFLOW, trading the amber vial and larger quantity for a cheaper entry point.
Our Store · Amber Vial · Tested
Get 50mg in Light-Blocking Amber Glass
Freedom Diagnostics-tested 5-Amino-1MQ, shipped in an amber vial to protect potency. On sale at $84.99 with another 10% off via code BRAINFLOW, around $76.49.
Shop Everest → Save 10% with BRAINFLOWSold for research use only.
My Take
Brainflow Verdict
5-Amino-1MQ is not the next Ozempic, and it is one of the more interesting metabolic research compounds going. The NNMT mechanism is elegant, the preclinical fat-loss signal is real and consistent, and the fact that it attacks fat through adipose biology instead of appetite makes it worth understanding even if you never touch it. The only real catch is timing. Consumer enthusiasm is well ahead of the human data, which is still close to zero. That is a reason to be careful, not dismissive. If you run it, dose in milligrams not micrograms, put diet and training around it, source tested material in an amber vial, and measure your bloodwork so you know whether it is doing anything.
5-Amino-1MQ FAQ
Is 5-Amino-1MQ a peptide?
No. It is a small synthetic molecule with no amino-acid chain, sold and discussed alongside peptides, which is where the confusion comes from. It is an NNMT inhibitor.
Does it cause weight loss?
In obese mice, NNMT inhibitors reduced fat mass without cutting food intake. There are no published human weight-loss trials, so human efficacy is not established. Promising in animals, unproven in people.
What is a common dose?
Commonly discussed oral ranges sit around 50 to 150 mg per day, often cycled 8 to 12 weeks. These are anecdotal, not validated, and this is not a dosing recommendation. The units are milligrams, not micrograms.
Is it better than semaglutide?
Not in any evidence-based sense. Semaglutide has large human trials and FDA approval. 5-Amino-1MQ has neither, and works through a different mechanism. They are not interchangeable.
Does the amber vial really matter?
Light protection helps. Like many research compounds it can degrade with UV and ambient light, and amber glass blocks most of that. Sealed, cold, dark storage protects potency, so vendors that ship it in amber vials have an edge on shelf stability.
Is it legal?
It is sold as a research compound, not a lawful supplement ingredient. It is not FDA-approved, not on the FDA’s 503A compounding list, and it is banned in tested sport. The “research use only” labeling is a gray area.
This article is for educational and research purposes only and is not medical advice. 5-Amino-1MQ is not FDA-approved to diagnose, treat, cure, or prevent any disease and is sold for research use only. Consult a qualified healthcare provider before starting any compound or protocol.
This article contains affiliate links. BrainFlow may earn a commission on qualifying purchases at no additional cost to the reader. We only recommend sources we trust.
